SCHEMBL1850284

SCHEMBL1850284

CN(C)CCNC(=O)Cc1c[nH]c2ccccc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.60
ALDH1A1 P00352 1/20 0.58
HTR1A P08908 2/20 0.57
HTR2A P28223 2/20 0.57
HTR2C P28335 2/20 0.57
HTR2B P41595 2/20 0.57
GAA P10253 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
ADRA2A P08913 1/20 0.56
ADRA2B P18089 1/20 0.56
ADRA2C P18825 1/20 0.56
MAOA P21397 1/20 0.56
ADRA1D P25100 1/20 0.56
HTR1B P28222 1/20 0.56
CHRNB4 P30926 1/20 0.56
CHRNA3 P32297 1/20 0.56
HTR7 P34969 1/20 0.56
ADRA1A P35348 1/20 0.56
HRH1 P35367 1/20 0.56
ADRA1B P35368 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7974113 0.89 LMNA (0.62) LMNAALDH1A1GAASMN1; SMN2KMT2A
SCHEMBL7976825 0.87 SMN1; SMN2 (0.71) LMNAALDH1A1GAASMN1; SMN2KMT2A
SCHEMBL10272692 0.85 MTNR1A (0.64) LMNAALDH1A1GAASMN1; SMN2KMT2A
SCHEMBL7972279 0.83 SMN1; SMN2 (0.66) LMNAALDH1A1GAASMN1; SMN2KMT2A
SCHEMBL1849735 0.83 LMNA (0.65) LMNAALDH1A1GAASMN1; SMN2KMT2A
SCHEMBL10069200 0.83 AANAT (0.77) LMNAALDH1A1KMT2AAANATPKM
SCHEMBL3594182 0.83 SMN1; SMN2 (0.61) LMNAALDH1A1GAASMN1; SMN2KMT2A
SCHEMBL2405544 0.83 MPO (0.61) HTR2ASLC6A4TSHRMTNR1A
SCHEMBL7972207 0.82 LMNA (0.67) LMNAALDH1A1GAASMN1; SMN2KMT2A
SCHEMBL2402894 0.82 LMNA (0.67) LMNAALDH1A1GAASMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242116-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2012-08-14 US disclosed
EP-2035436-B1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2011-05-25 EP disclosed
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-06-03 US disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors PI4KA, PDPK1, PIK3CA LMNA 4511/4885ALDH1A1 2279/4885HTR1A 1948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.